Open AccessDisrupting tumor onset and growth via selective cell tagging (SeCT) therapy
Author(s) -
Kenward Vong,
Tsuyoshi Tahara,
Sayaka Urano,
Igor Nasibullin,
Kazuki Tsubokura,
Yoichi Nakao,
Almira Kurbangalieva,
Hirotaka Onoe,
Yasuyoshi Watanabe,
Katsunori Tanaka
Publication year - 2021
Publication title -
science advances
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.928
H-Index - 146
ISSN - 2375-2548
DOI - 10.1126/sciadv.abg4038
Subject(s) - internalization , moiety , integrin , extracellular , extracellular matrix , cell , chemistry , cancer research , cell adhesion , cell growth , targeted therapy , in vivo , biochemistry , biology , cancer , stereochemistry , genetics
This study presents the early framework of selective cell tagging (SeCT) therapy, which is the concept of preferentially labeling specific cells in vivo with chemical moieties that can elicit a therapeutic response. Using glycosylated artificial metalloenzyme (GArM)-based protein labeling, this study reports two separate functional strategies. In one approach, early tumor onset can be suppressed by tagging cancer cells in living mice with an integrin-blocking cyclic-Arg-Gly-Asp (cRGD) moiety, thereby disrupting cell adhesion onto the extracellular matrix. In another approach, tumor growth in mice can be reduced by tagging with a cytotoxic doxorubicin moiety. Subsequent cell death occurs following internalization and drug release. Overall, experiments have shown that mouse populations receiving the mixture of SeCT labeling reagents exhibited a significant delay/reduction in tumor onset and growth compared with controls. Highlighting its adaptability, this work represents a foundational step for further development of SeCT therapy and its potential therapeutic applications.